amifostine anhydrous has been researched along with Fatigue in 3 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 9.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 5.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| " Xerostomia is a side effect of radiation therapy and, if not managed properly, can disrupt the patient's quality of life and lead to other health related issues." | 2.41 | Head and neck cancer: managing xerostomia and other treatment induced side effects. ( Gosselin, TK; Pavilonis, H, 2002) |
| "Patients with well-differentiated thyroid cancer have a good prognosis but a significant chance for local recurrence." | 1.32 | Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. ( Elkins, D; Goffman, TE; Karakla, D; Mason, ME; Mendoza, A; Shaffer, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gosselin, TK | 1 |
| Pavilonis, H | 1 |
| Mendoza, A | 1 |
| Shaffer, B | 1 |
| Karakla, D | 1 |
| Mason, ME | 1 |
| Elkins, D | 1 |
| Goffman, TE | 1 |
| Gelmon, K | 1 |
| Eisenhauer, E | 1 |
| Bryce, C | 1 |
| Tolcher, A | 1 |
| Mayer, L | 1 |
| Tomlinson, E | 1 |
| Zee, B | 1 |
| Blackstein, M | 1 |
| Tomiak, E | 1 |
| Yau, J | 1 |
| Batist, G | 1 |
| Fisher, B | 1 |
| Iglesias, J | 1 |
1 review available for amifostine anhydrous and Fatigue
| Article | Year |
|---|---|
Head and neck cancer: managing xerostomia and other treatment induced side effects.
Topics: Amifostine; Fatigue; Head and Neck Neoplasms; Humans; Pain; Pain Management; Skin Abnormalities; Tre | 2002 |
1 trial available for amifostine anhydrous and Fatigue
| Article | Year |
|---|---|
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Mod | 1999 |
1 other study available for amifostine anhydrous and Fatigue
| Article | Year |
|---|---|
Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Chronic Disease; Fatigue; Fem | 2004 |